A small first-in-human trial has reported a 94 percent sustained decrease in fragility fractures over two years among older women with advanced osteoporosis after they received their own stem cells, engineered with a sugar coating as a bone-marrow return address.
Researchers in Spain tracked ten female patients older than 50 with advanced osteoporosis who received a single infusion of their own mesenchymal stem/stromal cells (MSCs) decorated with a special sugar. Across the group, fractures fell from an average of eight per year in the two years before infusion to 0.5 per year in the two years afterward. Bone biopsies four months after the infusion showed that the average area occupied by bone tissue increased by about 70 percent. The findings are published in Cell.
The trial's results go beyond fracture reduction. Markers indicating bone formation remained elevated for six months after the medicine was given. Two years after the infusion, participants reported a 34 percent decrease in bone pain and a 30 percent reduction in disability scores. The authors say the decreased fracture incidence could not be ascribed to lifestyle changes or medication modifications, as no fractures occurred throughout the post-infusion period in those patients.
However, the study has limitations. The trial was small, had no control group, and most women were taking other osteoporosis drugs. Jan Schaefer, a physician commenting on LinkedIn, called the results a “fascinating experiment” but said the verdict is a few years away, noting that MSCs are larger than a lung capillary and that “on the first pass through the circulation 50 to 80 percent of them lodge in the lungs.” He also pointed out that because the group was selected at its worst moment, it is more likely to look better later on its own.
Ajit Varki, a physician-scientist at UC San Diego not involved in the study, told Nature that the results were "quite remarkable," showing "an almost 100 percent efficacy sustained for several years – and no side effects."
The human trial did not track the MSCs after infusion, so it is unclear how many reached the bone or how long they stayed there. Co-author Robert Sackstein holds intellectual-property rights to the cell-engineering technology used. Scientists at the University of Murcia are now preparing a follow-up trial with a larger cohort, which will randomize participants to receive engineered MSCs from their own bone marrow, engineered MSCs from a healthy donor, or no MSC treatment.
Analysis
Why This Matters
- Osteoporosis affects millions worldwide and is currently incurable; standard therapies slow bone loss but do not reverse it.
- A 94 percent reduction in fragility fractures could dramatically improve quality of life and reduce healthcare costs if confirmed in larger trials.
- The technique of tagging stem cells with a sugar coating could be applied to other diseases, as the team has already shown in diabetic mice.
Background
Osteoporosis occurs when the body loses bone faster than it can replace it, leaving the skeleton prone to fractures. Mesenchymal stem/stromal cells (MSCs) are the precursors of osteoblasts, the cells that create and repair bone. Scientists have long sought to use MSCs therapeutically, but when infused into the bloodstream, very few naturally end up where they are needed. Adding a sugar coating helps guide the cells to bone marrow, a method previously shown in mice.
Key Perspectives
Trial authors (University of Murcia researchers): The decreased fracture incidence cannot be attributed to lifestyle changes or medication modifications, and the findings raise the possibility of reversing some bone loss.
Jan Schaefer (physician): The trial is a fascinating experiment but the verdict is a few years away; 50 to 80 percent of infused MSCs lodge in the lungs, and without a control group it is uncertain whether the stem cells caused the fracture reduction.
Ajit Varki (UC San Diego physician-scientist): The results are "quite remarkable," showing almost 100 percent efficacy sustained for several years with no side effects.
What to Watch
- The follow-up randomized trial from the University of Murcia will compare self-donor MSCs, healthy-donor MSCs, and no MSC treatment in a larger group of advanced osteoporosis patients.
- Whether markers of bone formation and mineral density continue to improve over longer follow-up periods.
- Whether the same cell-engineering technique can be applied to other conditions, as early work in diabetic mice suggests.
Checked
12 claims in this story checked against 1 source: 12 supported.
Show each claim
- SupportedThe headline says an osteoporosis trial reported fewer fractures after an engineered stem-cell infusion.ScienceAlert: “After receiving a single infusion of their own engineered MSCs, enveloped in a special sugar, the patients showed a 94 percent sustained decrease in fragility fractures over the following two years.”
- SupportedThe summary says the first-in-human study found a 94 percent decrease in fragility fractures over two years and raises the possibility of reversing some bone loss.ScienceAlert: “The findings raise the possibility that this new MSC-technique can reverse some of the bone loss caused by osteoporosis, rather than simply slowing it.”
- SupportedThe trial followed ten women older than 50 with advanced osteoporosis after a single infusion of their own sugar-coated stem cells.ScienceAlert: “Their trial tracked 10 female patients older than 50 with advanced osteoporosis. After receiving a single infusion of their own engineered MSCs, enveloped in a special sugar”
- SupportedFractures fell from an average of eight per year in the two years before infusion to 0.5 per year in the two years afterward.ScienceAlert: “Across the group, fractures fell from an average of eight per year in the two years before infusion to 0.5 per year in the two years afterward.”
- SupportedFour-month bone biopsies showed the average area occupied by bone tissue increased by about 70 percent.ScienceAlert: “Four months after the infusion, bone biopsies revealed some positive signs. Across the group, the average area occupied by bone tissue increased by around 70 percent.”
- SupportedMarkers indicating bone formation remained elevated for six months after treatment.ScienceAlert: “The current study did not track the MSCs once they were infused into patients with osteoporosis, but markers that indicate bone formation remained elevated for half a year after the medicine was given.”
- SupportedParticipants reported a 34 percent decrease in bone pain two years after infusion.ScienceAlert: “Two years after the infusion, participants reported a decrease in bone pain of 34 percent”
- SupportedParticipants reported a 30 percent reduction in disability scores two years after infusion.ScienceAlert: “Two years after the infusion, participants reported a decrease in bone pain of 34 percent and a reduction in disability scores of 30 percent.”
- SupportedJan Schaefer called the results a “fascinating experiment” and said the verdict was a few years away.ScienceAlert: “On LinkedIn, physician Jan Schaefer calls this a "fascinating experiment," but says the verdict is a few years away.”
- SupportedSchaefer said that on the first pass through circulation, 50 to 80 percent of MSCs lodge in the lungs.ScienceAlert: “"MSCs are 20 to 30 micrometers across, larger than a lung capillary, so on the first pass through the circulation 50 to 80 percent of them lodge in the lungs," explains Schaefer.”
- SupportedAjit Varki described the results as “quite remarkable” and said they showed “an almost 100 percent efficacy sustained for several years – and no side effects.”ScienceAlert: “Ajit Varki, a physician-scientist at UC San Diego who wasn't involved in the study, told Nature's Elie Dolgin that the results are "quite remarkable." The trial, said Varki, "showed an almost 100 percent efficacy sustained for several years – and no side effects".”
- SupportedThe trial had no control group, most participants were taking other osteoporosis drugs, and a larger follow-up trial is being prepared with three treatment arms.ScienceAlert: “There was no control group, and most of the women were taking other osteoporosis drugs.”